This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
DOSTINEX is generally well tolerated1-3
In clinical trials, most side effects were mild to moderate while taking DOSTINEX.2,3
The most common side effects experienced included nausea, headache and dizziness.1-3
Full list of adverse events:4
The following undesirable effects have been observed and reported during treatment with DOSTINEX with the following frequencies: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to ≤1/100); rare (≥1/10,000 to≤1/1,000); very rare (≤1/10,000), not known (cannot be estimated from the available data)1
Example
Example
* Very common in patients treated for hyperprolactinaemia disorders; common in patients treated for inhibition/suppression of lactation.
** Common in patients treated for hyperprolactinaemia disorders; uncommon in patients treated for inhibition/suppression of lactation.
*** Very common in patients treated for hyperprolactinaemia disorders; uncommon in patients treated for inhibition/suppression of lactation.
Patients with these conditions should not take DOSTINEX:
Hypersensitivity to cabergoline, any of the excipients listed in Dostinex (cabergoline) Prescribing Information, or any ergot alkaloid
History of pulmonary, pericardial and retroperitoneal fibrotic disorders
Cabergoline is contraindicated in patients with hepatic insufficiency and with toxaemia of pregnancy
Cabergoline should not be co-administered with anti-psychotic medications or administered to women with a history of puerperal psychosis.
For long-term treatment: Evidence of cardiac vulvulopathy as determined by pretreatment echocardiography
See Dostinex (cabergoline) Prescribing Information for Special warnings and precautions for use.
Explore more including a snapshot of DOSTINEX and a video explaining how DOSTINEX works to lower prolactin levels
Learn more about the dosing for DOSTINEX
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021